2016 Access Compliance DEA 
NORML
AUGUST 26, 2019
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 30, 2019
Access the full document at. To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. Senator Grassley Questions Pages 6 & 7.
SMPL
AUGUST 14, 2019
Though ABA specified that it was not taking a position on marijuana legalization generally, it recognized that conflicting federal and state cannabis policies are untenable and have created complications for cannabis businesses operating in compliance with state law.
CannaMD
SEPTEMBER 15, 2020
SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. In March, 2016, State Bill 307 expanded access to full-strength medical marijuana to terminally ill patients who were determined by two doctors to have less than a year to live.
Cannabis Law Report
JANUARY 13, 2022
1, Louisiana’s medical cannabis program allows patients to access smokable whole-plant flower marijuana. 1, out-of-state medical marijuana patients may access Arkansas’ program to purchase cannabis for up to 90 days. This DEA guidance and the Kansas opinion both suggest legality for some hemp-derived delta-8 products under the 0.3
Cannabis Law Report
NOVEMBER 2, 2021
The investigation covered a lot of important ground, but the main results concern the levels of delta-9 THC in each product, the inaccuracy of the labeling, how easily minors can get access to products and whether companies test for impurities. The second argument is based on a DEA interim final rule on the topic of synthetic THC.
Expert insights. Personalized for you.
166 
Let's personalize your content